WESPAC Advisors’s Novo Nordisk NVO Stock Holding History

WESPAC Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$686K	Buy	+18,088	New	+$834K	0.35%	87

Other funds holding NVO

Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return

Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return

Nichols & Pratt Advisers Boston, Massachusetts $1.68B AUM 20.22% 1-Year Est. Return

Corda Investment Management Houston, Texas $1.52B AUM 30.53% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return

Cantor Fitzgerald Investment Advisors New York $1.81B AUM 23.74% 1-Year Est. Return

Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Viking Fund Management Minot, North Dakota $1.14B AUM 32.65% 1-Year Est. Return

WESPAC Advisors's NVO Position: Q3 2026 in Review

WESPAC Advisors opened a new position in Novo Nordisk (NVO) in Q3 2026: 18,088 shares worth $686K. The stake represents 0.35% of the portfolio and ranks #87 among its holdings.

372 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

WESPAC Advisors held 18,088 shares of Novo Nordisk worth $686K as of Q3 2026.
Novo Nordisk was a new WESPAC Advisors position in Q3 2026.
Novo Nordisk made up 0.35% of WESPAC Advisors's portfolio in Q3 2026, its #87 holding.
372 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on WESPAC Advisors's 13F filing for Q3 2026, filed 26 Oct 2026.